Back

Dapagliflozin enhances arterial and venous compliance during exercise in heart failure with preserved ejection fraction

31 August 2024 (09:00 - 09:30)
Organised by: Logo
Congress Presentation Part of: Diagnosis and prognosis of HFpEF Heart Failure with Preserved Ejection Fraction (HFpEF) ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Atsushi Tada

Mayo Clinic, Rochester (United States of America)

3 More presentations in this session

Presentation thumbnail
Estimated transmitral E- and A-wave overlapping predicted prognosis in patient with heart failure with preserved ejection.
Doctor K. Iwakura (Osaka, JP)
Abstract Slides Video
Presentation thumbnail
Diagnosis of heart failure with preserved ejection fraction based on exercise stress echocardiography in real-world practice
Mr Y. Tani (Maebashi, JP)
Abstract Slides Video
Presentation thumbnail
Diagnosing heart failure with preserved ejection fraction in patients with unexplained dyspnoea using left ventricular pressure-volume loops at rest and on exertion
Doctor R. Gessner (Leipzig, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Diagnosis and prognosis of HFpEF

The Event

Event poster

ESC Congress 2024

31 August 2024 09:00 CET
You may be interested in
thumbnail
Congress Presentation
Dapagliflozin effect on cardiopulmonary function, reverse cardiac remodelling and biomarkers in a cohort of HFrEF patients
thumbnail
Congress Presentation
Dapagliflozin's influence on cardiac remodeling in chronic heart failure patients
thumbnail
Congress Presentation
The effect of dapagliflozin on the microvascular endothelial cell function and metabolism in patients with heart failure: a preliminary report

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources